Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma

Shripad Banavali (1, 2) , Eddy Pasquier (3) , Nicolas Andre (3, 4)

1 Tata Memorial Centre
2 Metronomics Global Health Initiative
3 CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie
4 Service de pédiatrie, d'hématologie et d'oncologie [Hôpital de La Timone - APHM]

We report here a case of a 69-year-old woman with a relapsing metastatic angiosarcoma treated with a combination of metronomic chemotherapy and propranolol. The beta blockers were added since the tumour was positive for betaadrenergic receptor. A complete response was quickly obtained and lasted for 20 months. With this case, the combination of metronomic chemotherapy and propranolol in angiosarcoma warrants additional studies and illustrates the potential of metronomics to generate innovative yet inexpensive targeted therapies for both high-income and low-/middle-income countries.

Mots clés: etoposide; celecoxib; palliative treatment; beta-blockers; metronomic chemotherapy; propranolol; drug repositioning; angiosarcoma; cyclophosphamide

Domaines: Cancer; Médicaments

Shripad Banavali, Eddy Pasquier, Nicolas Andre. Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma. Ecancermedicalscience, 2015, 9, ⟨10.3332/ecancer.2015.499⟩. ⟨hal-01420003⟩